Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07025811 · ClinicalTrials.gov registry record · Phase 4
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
A Phase 4 study of Dry Eye Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
- 5
- Study locations
NCT07025811: Recruiting Phase 4 study of Dry Eye Disease, sponsored by Hoffmann-La Roche.
NCT07025811 is a Phase 4 study of Dry Eye Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 350 participants, above the 244-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (43% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07025811, a Phase 4 study of Dry Eye Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
Conditions Studied
Interventions
- DRUG Vevye®
- DRUG Xiidra®
Study Locations (5)
Kentucky
- Butchertown Clinical Trials - Louisville
Massachusetts
- Andover Eye Associates - Andover
North Carolina
- Oculus Research - Garner
Tennessee
- Total Eyecare, P.A. - Memphis
Virginia
- Piedmont Eye Center - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 4 |
What NCT07025811 shows while recruiting
NCT07025811 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 244-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Vevye® is the first listed.
NCT07025811 lists 5 locations in 5 states (Kentucky, Massachusetts, North Carolina).
Frequently Asked Questions
What is clinical trial NCT07025811 about?
NCT07025811 is a clinical study titled "A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment". This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
What is the current status of trial NCT07025811?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2025-07-09. Estimated completion is 2026-04-30.
What conditions does trial NCT07025811 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07025811?
The interventions under investigation include: Vevye® (DRUG), Xiidra® (DRUG).
Who is sponsoring clinical trial NCT07025811?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07025811 being conducted?
This trial has 5 study locations across Kentucky, Massachusetts, North Carolina, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07025811's enrollment target sits among peer trials
350 7th of 33 higher than 27 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
RECRUITING
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI